Evidence map›Paper›PMID 40472739›Full record

ArticleNeoplasia (New York, N.Y.)2025

Deletion of the transcription factor ATF4 in a model of clear cell renal cell carcinoma.

Yuling Chi, Shireen Chikara, Eduardo Mere Del Aguila, Tuo Zhang, Jacob B Geri, David M Nanus, Lorraine J Gudas

Abstract read
In one paragraph

Article in Neoplasia (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. ATF4 in proximal tubules modulates kidney function and modifies the metabolome.Journal of molecular medicine (Berlin, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuling ChiPharmacology Department, Weill Cornell Medicine of Cornell University, 1300 York Ave, New York, NY 10065, USA.
Shireen ChikaraPharmacology Department, Weill Cornell Medicine of Cornell University, 1300 York Ave, New York, NY 10065, USA.
Eduardo Mere Del AguilaPharmacology Department, Weill Cornell Medicine of Cornell University, 1300 York Ave, New York, NY 10065, USA.
Tuo Zhangthe Genomics Core, Weill Cornell Medicine of Cornell University, 1300 York Ave, New York, NY 10065, USA.
Jacob B GeriPharmacology Department, Weill Cornell Medicine of Cornell University, 1300 York Ave, New York, NY 10065, USA.
David M Nanusthe Department of Medicine, Weill Cornell Medicine of Cornell University, 1300 York Ave, New York, NY 10065, USA.
Lorraine J GudasPharmacology Department, Weill Cornell Medicine of Cornell University, 1300 York Ave, New York, NY 10065, USA; the Department of Medicine, Weill Cornell Medicine of Cornell University, 1300 York Ave, New York, NY 10065, USA. Electronic address: ljgudas@med.cornell.edu.

Funding

CANCER PHARMACOLOGYT32CA062948 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LORRAINE J GUDAS · 1994 to 2026
$12.1M
Gene Nutrient Interactions in Kidney FunctionR01DK113088 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI GUDAS, LORRAINE J · 2018 to 2025
$3.7M
NCI NIH HHS T32 CA062948NIDDK NIH HHS R01 DK113088
6 · The paper itself

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common form of kidney cancer in adults. We generated TRAnsgenic of Cancer of the Kidney (TRACK) mice that express a triple-mutant (P402A, P564A, and N803A) human HIF1α construct specifically in their proximal tubule (PT) cells. We demonstrated that the elevated lipid content found in human ccRCCs is mimicked in these TRACK PT cells. Additionally, we reported that ATF4 (activating transcription factor 4), a transcription factor, and its target genes were highly expressed both in human ccRCCs and in TRACK PT cells. To delineate the functions of ATF4 in ccRCC we have now generated TRACK mice in which the ATF4 gene is specifically deleted in PT cells (GCREA∆T). Our genome-wide transcriptomics and proteomics studies show that expression of ∼20 % of mRNAs and proteins is significantly altered in GCREA∆T compared to TRACK kidney cortices. Gene set enrichment analyses (GSEAs) of mRNAs demonstrate that the fatty acid metabolism pathway is upregulated in TRACK vs WT and that, conversely, ATF4 deletion reduces mRNAs in the fatty acid metabolism pathway (e.g., ATP citrate lyase). Moreover, some transcripts elevated in human ccRCC are reduced in GCREA∆T vs. TRACK kidney cortices and cystic, pre-cancerous lesions are also reduced. Thus, ATF4 actions increase both lipid droplet accumulation in this ccRCC model and oncogenesis-related gene expression. These data suggest that ATF4 contributes to the formation of ccRCC tumors and may be a potential therapeutic target.

Indexed as

Activating Transcription Factor 4Carcinoma, Renal CellGene DeletionKidney NeoplasmsAnimalsDisease Models, AnimalGene Expression Regulation, NeoplasticHumansHypoxia-Inducible Factor 1, alpha SubunitMiceMice, TransgenicActivating Transcription Factor 4ATF4 protein, humanHypoxia-Inducible Factor 1, alpha SubunitActivating transcription factor 4ATP citrate lyaseClear cell renal cell carcinomaFatty acidsProteomicsTranscriptomics

Identifiers

PMID40472739
PMCPMC12172298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.